Author

A. A. Hamid

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1

Frequent Co-Authors

C. J. Sweeney· 2 shared D. L. Burkhart· 2 shared K. L. Morel· 2 shared L. Ellis· 2 shared A. D. Choudhury· 1 shared A. G. Sowalsky· 1 shared A. M. Bergman· 1 shared A. Mitrofanova· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Sweeney

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer

K. L. Morel, A. A. Hamid, B. G. Falcon, J. N. Singh, S. Linder, A. M. Bergman, H. G. van der Poel, I. Hofland, E. M. Bekers, S. Trostel, S. Wilkinson, A. T. Ku, D. L. Burkhart, M. Kim, J. Kim, , L. Ellis

This study shows that loss of ZFP36 promotes NF-κB activation and phenotypic plasticity in prostate cancer, leading to aggressive disease and castration resistance, which can be reversed by NF-κB inhibition.

bioRxiv · Aug 5, 2022 · PreprintCancer Biology

Abnormal Recovery from Acute Stress in Huntingtons Disease Mice

L. A. Zacharoff, A. A. Hamid, W. C. Engeland, J. M. Dubinsky

This study examines corticosterone levels and recovery from stress in HD mouse models, finding slowed stress recovery in R6/2 mice but no major disruption in glucocorticoid signaling.

bioRxiv · Jul 21, 2021 · PreprintNeuroscience

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology